Tishas Additional Liability Company Pharmaceutical Import Profile — Belarus (DGFT 2022–2026)

Name: Tishas Additional Liability Company Pharmaceutical Import Records from India — 2 Products, $124.9K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Tishas Additional Liability Company — Pharmaceutical Importer Profile (2026) | 2 Products, $124.9K Trade | TransData Nexus

Tishas Additional Liability Company

Pharmaceutical Importer · Belarus · Advanced Oncology Focus · $124.9K Total Trade · DGFT Verified

Tishas Additional Liability Company is a pharmaceutical importer based in Belarus with a total trade value of $124.9K across 2 products in 1 therapeutic categories. Based on 4 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Tishas Additional Liability Company sources from 3 verified Indian suppliers, with Mylan Laboratories Limited accounting for 64.0% of imports.

Tishas Additional Liability Company — Import Portfolio & Supplier Network

Tishas Additional Liability Company import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Tishas Additional Liability Company?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Mylan Laboratories Limited	$434.3K	9	64.0%
Sp Accure Labs Private Limited	$222.5K	8	32.8%
Trugen Pharmaceuticals Private Limited	$21.7K

What Formulations Does Tishas Additional Liability Company Import?

Formulation	Value	Ships
Tenofovir disoproxil fumarate 300 MG+	$150.0K	3
Efavirenz 600 MG tablets 30s	$145.4K	3
Pazo span 400 pazopanib tablets 400MG	$50.0K	1
Benda spal-p 100 (bendamustinehydrochlor	$50.0K	1
Pazo span 400 pazopanib tablets 400MG Pack size 30 s Pack	$50.0K	1
Tenofovir disoproxil fumarate 300MG +	$50.0K	1
Tenofovir disoproxil fumarate 300 MG +	$50.0K	1
Myhep dvir -- dacl/sofo TAB 60/400MG	$38.9K	1
Mito spal 20(mitoxantrone concentrate	$24.9K	2
Benda spal-p25 (bendamustine	$24.8K	1
Tarcesp 150 (erlotinib Film-Coated	$12.8K	1
Methylprednisolone 8MG TAB 3x10 batch	$11.3K	1
Methylprednisolone 8 MG TAB 3x10 batch	$10.4K	1
Doce spal-l 20 (docetaxel coacentrate	$10.1K	1

Tishas Additional Liability Company imports 14 distinct pharmaceutical formulations. Showing top 14 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Pazopanib	Advanced Oncology	$100.0K	2	1.2%	6
2	Mitoxantrone	Advanced Oncology	$24.9K	2	1.3%	5

Tishas Additional Liability Company imports 2 pharmaceutical products across 1 categories into Belarus totaling $124.9K.

Tishas Additional Liability Company — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Tishas Additional Liability Company is a pharmaceutical importer based in Minsk, Belarus. The company specializes in the procurement of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, primarily from India. With a total import value of $125,000 USD over four shipments, Tishas Additional Liability Company demonstrates a focused approach to sourcing specific therapeutic products. The company's portfolio is entirely concentrated on two products within the Advanced Oncology therapeutic category, indicating a strategic emphasis on oncology treatments. This specialization suggests that Tishas Additional Liability Company plays a significant role in supplying critical oncology medications to the Belarusian market, addressing the therapeutic needs of patients requiring advanced cancer care.

2Distribution Network

While specific details about Tishas Additional Liability Company's warehouse locations and logistics capabilities are not publicly available, the company's import activities indicate a structured distribution network within Belarus. The four shipments from India, totaling $125,000 USD, suggest a consistent and reliable logistics operation. Given the focus on oncology products, it is likely that the company collaborates with healthcare institutions, pharmacies, and hospitals across Belarus to ensure timely and efficient delivery of these critical medications. The strategic sourcing from India, a major global supplier of generic pharmaceuticals, further implies that Tishas Additional Liability Company has established robust international logistics partnerships to facilitate the importation and distribution of its products.

3Industry Role

Tishas Additional Liability Company functions as a pharmaceutical importer specializing in the acquisition of finished pharmaceutical formulations from India. Its role in the Belarusian pharmaceutical supply chain is pivotal, particularly in the oncology sector, where access to specialized treatments is essential. By focusing exclusively on two oncology products, the company positions itself as a niche supplier, catering to a specific market segment that requires advanced cancer therapies. This strategic focus allows Tishas Additional Liability Company to develop expertise in the oncology domain, ensuring that it can meet the unique demands of healthcare providers and patients seeking these specialized medications.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Tishas Additional Liability Company

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Tishas Additional Liability Company's sourcing strategy is highly concentrated, with all imports originating from three Indian suppliers: Mylan Laboratories Limited, SP Accure Labs Private Limited, and Trugen Pharmaceuticals Private Limited. Mylan Laboratories Limited is the predominant supplier, accounting for 64% of the total import value, followed by SP Accure Labs Private Limited at 32.8%, and Trugen Pharmaceuticals Private Limited at 3.2%. This concentration indicates a strategic choice to establish strong, reliable partnerships with select suppliers, potentially ensuring consistent product quality and supply chain stability. However, such dependency on a limited number of suppliers also poses risks, including vulnerability to supply disruptions or changes in supplier policies. The shipment data reveals a stable relationship with these suppliers, as evidenced by the consistent import volumes over the period. Nonetheless, diversifying the supplier base could mitigate potential risks associated with over-reliance on a few sources.

2Supply Chain Resilience

Tishas Additional Liability Company's supply chain resilience appears robust, given the consistent importation of oncology products from three established Indian pharmaceutical manufacturers. The company's focus on finished pharmaceutical formulations suggests a streamlined procurement process, potentially reducing complexities associated with raw material sourcing and manufacturing. While the current supplier base is limited, the company's strategic emphasis on oncology products indicates a deep understanding of this therapeutic area, which may facilitate effective collaboration with suppliers. To further enhance supply chain resilience, Tishas Additional Liability Company could consider identifying and establishing relationships with additional suppliers, thereby reducing dependency and increasing flexibility in sourcing.

Importing Pharmaceuticals into Belarus — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Belarus

1Regulatory Authority & Framework

In Belarus, the Ministry of Health is the primary regulatory authority overseeing the pharmaceutical sector, including the importation and registration of medicinal products. The "On Medicines" Law, dated July 20, 2006, No. 161-Z, establishes the framework for the circulation of medicines, encompassing their import, export, production, and distribution. This legislation ensures that all pharmaceutical products meet the required safety, efficacy, and quality standards before entering the Belarusian market. Additionally, the Resolution of the Council of Ministers of the Republic of Belarus No. 1269, dated September 2, 2008, outlines the procedures for the state registration and re-registration of medicinal products and pharmaceutical substances, further detailing the regulatory requirements for pharmaceutical imports.

2Import Licensing & GMP

Import licensing in Belarus is governed by the Ministry of Health, which issues licenses for pharmaceutical activities, including the importation of medicinal products. To obtain an import license, companies must comply with the Good Manufacturing Practice (GMP) standards, ensuring that imported pharmaceuticals are produced and controlled according to quality standards. The technical code TKP 030-2017 (33050) establishes the principles and rules of GMP for medicines, including pharmaceutical substances used in pharmaceuticals. This code applies to all types of medicines and determines the general requirements for their production and quality control.

Tishas Additional Liability Company — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Tishas Additional Liability Company's exclusive focus on two oncology products—Pazopanib and Mitoxantrone—indicates a strategic decision to specialize in the oncology therapeutic area. This specialization allows the company to develop in-depth knowledge and expertise in oncology treatments, positioning it as a key supplier of these critical medications within Belarus. The market demand for advanced oncology therapies is significant, driven by the increasing prevalence of cancer and the need for effective treatments. By concentrating on these specific products, Tishas Additional Liability Company can ensure a consistent supply of high-quality oncology medications, meeting the therapeutic needs of healthcare providers and patients.

2Sourcing Profile

Tishas Additional Liability Company's sourcing strategy is centered on importing finished pharmaceutical formulations from India, a leading global supplier of generic medicines. The company's focus on finished products, rather than active pharmaceutical ingredients (APIs), suggests a streamlined procurement process that emphasizes the quality and regulatory compliance of the final product. By sourcing from India, Tishas Additional Liability Company benefits from the country's established pharmaceutical manufacturing capabilities and adherence to international quality standards. This approach ensures that the imported oncology medications meet the required safety and efficacy standards for the Belarusian market.

Seller's Guide — How to Become a Supplier to Tishas Additional Liability Company

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

For new Indian suppliers, Tishas Additional Liability Company's focused sourcing strategy presents both opportunities and challenges. The company's established relationships with current suppliers may limit the potential for new partnerships. However, if new suppliers can offer competitive pricing, superior product quality, or additional value-added services, there may be opportunities to collaborate with Tishas Additional Liability Company.

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Tishas Additional Liability Company

What products does Tishas Additional Liability Company import from India?

Tishas Additional Liability Company imports 2 pharmaceutical products across 1 categories. Top imports: Pazopanib ($100.0K), Mitoxantrone ($24.9K).

Who supplies pharmaceuticals to Tishas Additional Liability Company from India?

Tishas Additional Liability Company sources from 3 verified Indian suppliers. The primary supplier is Mylan Laboratories Limited (64.0% of imports, $434.3K).

What is Tishas Additional Liability Company's total pharmaceutical import value?

Tishas Additional Liability Company's total pharmaceutical import value from India is $124.9K, based on 4 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Tishas Additional Liability Company focus on?

Tishas Additional Liability Company imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full Tishas Additional Liability Company Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.